Shares of Merck were on the rise in Monday trading after the pharmaceutical giant received an upgrade and some optimistic words from a Goldman Sachs analyst. According to the firm, Merck is one of their all time favorite stocks because of the company’s blockbuster drug Keytruda’s lung cancer breakthrough. Analyst Jami Rubin of Goldman wrote … Continue reading “Merck Just Received an Upgrade from Goldman Sachs for This Reason”
